Repinatrabit clinical trials
Also written JNT-517.
How each study uses repinatrabit is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the repinatrabit studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (7)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test repinatrabit, phase 3 first.
- Nov 2027A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPhase 3 · Otsuka Pharmaceutical Development & Commercialization, Inc.
- Nov 2026A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered TogetherPhase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc.
- Feb 2027A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney FunctionPhase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc.
Studies
Open first, then newest update. How each study uses repinatrabit is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)RecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06971731Written as JNT-517
- A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered TogetherRecruitingPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07446400Written as Repinatrabit
- A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney FunctionRecruitingPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07713758Written as Repinatrabit
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06628128Written as JNT-517
- First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaCompletedPhase 1/2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05781399Written as JNT-517 Suspension
- A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06637514Written as JNT-517 Tablet
- How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male ParticipantsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07573449Written as [14C]-JNT-517
Codes
What other systems call repinatrabit · ClinicalTrials.gg INT015098
- UNII (FDA) 5P44NDU6ACREPINATRABITOne source FDA
- NCI Thesaurus C213387RepinatrabitOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5P44NDU6AC | REPINATRABIT | One source FDA |
| NCI Thesaurus | C213387 | Repinatrabit | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.